Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Impliant Inc..

This article was originally published in Start Up

Executive Summary

Emboldened by recent acquisitions in its industry, Impliant Inc. is beginning pivotal US trials on TOPS, a spinal stablization device that could offer surgeons an alternative to fusion.

You may also be interested in...



In Brief

Brief summaries of recent developments in the medical device industry.

Business & Technology Briefs (02/2007)

A short summary of recent market and product developments covering Peripheral Interventions, Cardiovascular and Orthopedic/Spine Surgery, and Oncology.

Start-Up News: New Twists in Spine and Orthopedics

A brief discussion of a few new companies in the spine and orthopedic surgery market that presented at Medtech Insight and Windhover Information's IN SPINE & ORTHOPEDICS conference in Las Vegas, December 2006.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT037404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel